Clinical Trial: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07222553) titled 'Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD' on Oct. 28.

Brief Summary: The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.

Study Start Date: Feb. 27, 2026

Study Type: INTERVENTIONAL

Condition: Immunoglobulin G4-related Disease

Intervention: DRUG: Inebilizumab

Inebilizumab will be administered via IV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Amgen

Publis...